Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.44 |
| ▸ | TACR2 | P21452 | 3/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980158 | 0.94 | EPHX2 (0.42) | TACR1TACR2CCR5 | |
| SCHEMBL3983335 | 0.92 | CCR5 (0.41) | TACR1TACR2CCR5CYP3A4CYP2D6 | |
| SCHEMBL3981258 | 0.90 | TACR2 (0.37) | TACR1TACR2CCR5ALDH1A1 | |
| SCHEMBL9029048 | 0.89 | TACR2 (0.42) | TACR1TACR2CCR5TACR3CYP3A4 | |
| SCHEMBL9026960 | 0.89 | TACR2 (0.42) | TACR1TACR2CCR5TACR3CYP3A4 | |
| SCHEMBL3980418 | 0.89 | TACR2 (0.50) | TACR1TACR2CCR5TACR3CYP3A4 | |
| SCHEMBL3981253 | 0.88 | TACR1 (0.39) | TACR1TACR2CCR5 | |
| SCHEMBL9027646 | 0.87 | TACR2 (0.42) | TACR1TACR2CCR5TACR3 | |
| SCHEMBL9027505 | 0.87 | TACR2 (0.42) | TACR1TACR2CCR5TACR3 | |
| SCHEMBL3987361 | 0.84 | CNR1 (0.39) | TACR1TACR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754701-A1 | SULFONYLOXY DERIVATIVES | Sankyo Company, Limited (JP) | 2007-02-21 | — | — | EP | claimed |
| US-7560549-B2 | Sulfonyloxy derivatives | SANKYO COMPANY, LIMITED (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20070135434-A1 | Sulfonyloxy derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1754701-A1 | SULFONYLOXY DERIVATIVES | Sankyo Company, Limited (JP) | 2007-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135434-A1 | Sulfonyloxy derivatives | TACR1, NPSR1, TACR2 | TACR1 1/4885TACR2 3/4885CCR5 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.